[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anal-fistula\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anal-fistula":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,51,76,106,130,167,194,216,238,264,294,702,723,753,779,803],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100645321","laser-ablation-versus-conventional-fistulectomy-for-uncomplicated-perianal-fistula-100645321",false,"NCT07681531","Laser Ablation Versus Conventional Fistulectomy for Uncomplicated Perianal Fistula","Comparison Between Conventional Surgery and Laser Ablation for Uncomplicated Perianal Fistula","Inclusion Criteria:\n\n* Age 18 to 55 years.\n* Male and female patients.\n* Scheduled for surgical treatment of uncomplicated perianal fistula.\n* Single fistula tract.\n* Less than 30% involvement of the external anal sphincter.\n* Penetration of tract limited to subcutaneous tissue.\n\nExclusion Criteria:\n\n* Recurrent fistula.\n* Complex fistula.\n* History of gut malignancy.\n* History of inflammatory bowel disease.\n* Patients unfit for anesthesia.","ALL","18 Years","55 Years",{"count":20,"type":21},72,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized controlled trial aims to compare conventional open fistulectomy and laser ablation in the treatment of uncomplicated perianal fistula. The study will evaluate postoperative recovery time and recurrence rates between the two procedures. A total of 72 patients with uncomplicated perianal fistula will be randomly assigned to either conventional open fistulectomy or laser ablation and followed for six months after surgery.",[27,28],"Perianal Fistula","Anal Fistula",[30,31,32,33,34,35,36,37],"Perianal fistula","Anal fistula","Laser ablation","Laser-assisted anal fistula surgery","FiLaC","Fistulectomy","Conventional surgery","Randomized controlled trial","NOT_YET_RECRUITING","2026-06-26",{"date":41,"type":42},"2026-07-02","ACTUAL",{"date":44,"type":21},"2026-07-01",{"date":46,"type":21},"2027-03-31",{"name":48,"class":49},"PNS Hafeez - Naval Hospital","OTHER_GOV",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":50},"100514114","study-on-the-treatment-of-anal-fistulas-using-alofisel-versus-fat-autologous-stem-cells-100514114","NCT05974280","Study on the Treatment of Anal Fistulas Using Alofisel Versus Fat Autologous Stem Cells","Pilot Study on the Treatment of Anal Fistulas in Crohn's Disease Patients Using Alofisel Versus Fat Autologous Stem Cells","CHAZAM","Inclusion Criteria:\n\n* Complex anal fistula with the following criteria: - Inactive\u002Fslightly active luminal Crohn's disease under conventional treatment or biotherapy MRI has demonstrated effective drainage. Maximum of two internal orifices and three external orifices; persists despite internal orifice(s) closing.\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding women\n* Patients hypersensitive to the product, bovine serum or any of the excipients of Alofisel\n* Vulnerable persons: deprived of liberty, under guardianship, under curatorship, etc.",{"count":60,"type":21},20,"OBSERVATIONAL","One of the newest and most innovative medicinal approaches is cell therapy. Several clinical trials and experimental investigations have looked into the feasibility of treating CD-related fistulas with stem cells.\n\nThe current indication for ALOFISEL® (active ingredient: Darvadstrocel) is the treatment of difficult perianal Crohn's fistulas that have not responded well to at least one conventional therapy or biotherapy.\n\nThis brand-new cell therapy medication is created using amplified allogeneic human adult mesenchymal stem cells from adipose tissue (ADSC). The supplier mandates that two patients be booked for a single dose of ALOFISEL® due to the medication's expensive price-roughly €54,000 for a single dose of 120 million-which cannot be stored once thawed.\n\nOnly one of the two patients receives therapy; the other serves as the backup patient. By doing this, another \"back-up\" patient who might receive no care at all is avoided.\n\nAn developing alternate approach to allogeneic ADSC injection for the treatment of complicated anal fistulas in CD is autologous fat injection. In recent years, autologous fat grafts have been the subject of in-depth research. They are popular because it is simple to get clinical samples (lipoaspirate, adipose tissue), and because there are a lot of ADSCs in adipose tissue. Additionally, ADSCs show strong immunomodulatory and regenerative capacities.\n\nWe would wish to compare the effectiveness of these two injection kinds on perianal fistulas as part of our care of CD.",[64,28],"Crohn Disease","RECRUITING","2026-06-23",{"date":68,"type":42},"2026-06-24",{"date":70,"type":42},"2024-01-02",{"date":72,"type":21},"2027-06-02",{"name":74,"class":75},"Nantes University Hospital","OTHER",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":86,"studyType":61,"phases":4,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":50},"100629655","recurrence-and-anal-fistula-patient-reported-outcomes-trial-100629655","NCT07477496","Recurrence and Anal Fistula Patient Reported Outcomes Trial","Prospective Study of Functional Disorders and Quality of Life Following Surgical Management of Perianal Fistulas","RAPPORT","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Clinically and\u002For radiologically confirmed perianal fistula (primary or recurrent).\n* Planned definitive surgical treatment (any sphincter-dividing or sphincter-preserving technique).\n* Ability to understand and complete study questionnaires.\n* Commitment to attend follow-up visits at 1, 3, 6, and 12 months (or to complete remote assessments).\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Diagnosed inflammatory bowel disease (Crohn's disease or ulcerative colitis).\n* Active perianal sepsis requiring emergency drainage after enrolment and before definitive surgery.\n* Prior abdominoperineal resection or permanent colostomy.\n* Pregnancy or planned pregnancy during the 12-month follow-up.\n* Severe uncontrolled systemic disease (e.g., decompensated heart failure, end-stage renal disease, uncontrolled diabetes).\n* Cognitive impairment or psychiatric disorder precluding reliable consent or questionnaire completion.\n* Lack of reliable contact information or inability to attend at least one scheduled follow-up visit.",{"count":85,"type":21},100,"24 Months","Perianal fistulas are a chronic anorectal condition associated with significant morbidity, including pain, persistent discharge, infection, and impaired continence, all of which can substantially affect patients' quality of life. Surgical management aims to eradicate the fistulous tract while preserving anal sphincter function and continence.\n\nDespite numerous available surgical techniques, high-quality comparative evidence regarding optimal management remains limited. This prospective observational study aims to evaluate clinical outcomes, functional outcomes, and patient-reported quality of life following surgical treatment of perianal fistulas.\n\nThe study will collect both clinician-reported and patient-reported outcomes over a 12-month follow-up period. Outcomes of interest include fistula healing, recurrence, postoperative complications, continence status, symptom burden, and health-related quality of life. The findings are expected to provide real-world data that may inform clinical decision-making and contribute to improved patient-centered care.",[89,28,27],"Anal Fistula Surgery",[91,92,93,94,95,96],"perianal","fistula","anal","PROMs","patient-reported outcomes","quality of life","2026-03-17",{"date":99,"type":42},"2026-03-19",{"date":101,"type":42},"2026-01-01",{"date":103,"type":21},"2030-01-01",{"name":105,"class":75},"National and Kapodistrian University of Athens",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":4},"100630020","impact-of-surgical-timing-on-anal-fistula-outcomes-100630020","NCT07482241","Impact of Surgical Timing on Anal Fistula Outcomes","Does the Duration Between Symptom Onset and Surgical Intervention Affect the Outcomes in Patients With Anal Fistula?","Inclusion Criteria:\n\n* Patients aged 18 years or older diagnosed with primary cryptoglandular anal fistula confirmed by clinical examination and preoperative imaging (MRI).\n* Patients who will be undergoing definitive surgical intervention for anal fistula at Assiut University Hospital between 2026 and 2028.\n* Complete medical records available, including documented symptom onset date (defined as first reported perianal pain, swelling, or discharge) and surgery date.\n* Minimum postoperative follow-up of 12 months, with clinical assessment data on healing and recurrence.\n\nExclusion Criteria:\n\n* Fistulas due to Crohn's disease, tuberculosis, malignancy, trauma, radiation, or obstetrical injury.\n* Pregnant women.\n* Recurrent anal fistulas or those with prior surgical intervention for the same fistula.\n* Incomplete records or loss to follow-up before 6 months postoperatively.\n* Patients with comorbidities precluding surgery (e.g., uncontrolled coagulopathy or active systemic infection).",{"count":114,"type":21},90,"This study aims to evaluate if the amount of time a person experiences symptoms of an anal fistula before having surgery affects their surgical outcomes and recovery.\n\nAn anal fistula is a chronic condition that typically requires surgery to heal properly. In routine clinical practice, many patients experience a significant delay before getting surgery due to a variety of reasons, such as under-reporting symptoms, misdiagnosis, or prolonged conservative treatments. Doctors want to understand if this delay in surgical intervention allows ongoing infection and scarring to complicate the surgery and worsen the patient's recovery.\n\nTo investigate this, researchers will observe 90 adult patients who are undergoing definitive surgery for a primary anal fistula. The participants will be divided into three groups based on how long they had symptoms before their operation:\n\n3 months or less Between 3 and 6 months More than 6 months\n\nThe main goal of the study is to compare these groups to see how many patients achieve complete clinical healing and how many experience a recurrence (the fistula returning) within 12 months after the surgery. Additionally, the study will track secondary outcomes, including how long it takes the wound to heal completely, any postoperative complications, changes in bowel control (fecal incontinence), pain resolution, and the patient's overall postoperative quality of life. The findings will help inform both doctors and patients on the optimal timing for anal fistula surgery.",[89,28,117],"Surgery Timing",[28,119,120,121],"Cryptoglandular Anal Fistula","Fistula in Ano","Anorectal Fistula","2026-03-16",{"date":99,"type":42},{"date":125,"type":21},"2026-05",{"date":127,"type":21},"2028-06",{"name":129,"class":75},"Assiut University",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":138,"targetDuration":140,"studyType":61,"phases":4,"briefSummary":141,"conditions":142,"keywords":149,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":166},"100458003","myriad-augmented-soft-tissue-reconstruction-registry-100458003","NCT05243966","Myriad™ Augmented Soft Tissue Reconstruction Registry","Registry of Myriad™ Utilization in Soft Tissue Reconstruction Procedures","MASTRR","Inclusion Criteria:\n\n* Willing and able to provide written informed consent and to comply with the requirements of Clinical Investigational Plan\n* Male or female patients aged 18 years or above\n* Patients where Matrix and\u002For Morcells were used as part of their soft tissue reconstruction procedure\n* Subject that are willing and able to comply with all aspects of the treatment and evaluation schedule\n\nExclusion Criteria:\n\n* Patients with known sensitivity to ovine (sheep) derived material\n* Patients with full thickness ('third degree') burns\n* Patients with wounds with uncontrolled clinical infection (CDC Contamination Grade=4)\n* Any medical condition or serious intercurrent illness that, in the opinion of the investigator, may make it undesirable for the patient to participate in the study\n* Patient is currently participating or has participated in another clinical study within past 30 days prior to enrollment\n* Pregnant or lactating women\n* Any subject who, at the discretion of the Investigator, is not suitable for inclusion in the study",{"count":139,"type":21},800,"12 Months","This is an observational study designed to evaluate the safety and clinical outcomes of Myriad™ in soft tissue reconstruction procedures. The study will enroll participants who are undergoing a surgical procedure, where the attending physician will use Myriad™ as part of the surgical intervention.",[143,144,145,146,28,147,148],"Abdominal Wound Dehiscence","Necrotizing Soft Tissue Infection","Lower Extremity Wound","Pilonidal Sinus","Hidradenitis Suppurativa","Pressure Injury",[150,151,152,153,154,155],"Soft tissue reconstruction","Limb salvage","Extracellular matrix","Soft tissue reinforcement","Wound reconstruction","Regenerative medicine","2026-02-17",{"date":158,"type":42},"2026-02-19",{"date":160,"type":42},"2022-01-10",{"date":162,"type":21},"2029-01",{"name":164,"class":165},"Aroa Biosurgery Limited","INDUSTRY",13,{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":179,"conditions":180,"keywords":183,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":4},"100617787","determining-the-effect-of-education-given-to-patients-undergoing-outpatient-anal-fistula-surgery-100617787","NCT07323160","Determining the Effect of Education Given to Patients Undergoing Outpatient Anal Fistula Surgery","Determining the Effect of Discharge Education Provided Using the Teaching-back Method on Readmission Rates and Patient Satisfaction in Patients Undergoing Same-day Anal Fistula Surgery","anal fistula","Inclusion Criteria:\n\n* Having a day surgery planned, Being admitted to the Proctology Unit for anal fistula surgery, Being undergoing elective anal fistula surgery for the first time, Being planned to have a surgical procedure performed with local anesthesia, Being over 18 years of age, Being able to read and understand Turkish, Being able to read and understand the research instructions, Being literate, Agreeing to participate in the research.\n\nExclusion Criteria:\n\n* Having surgery planned with general anesthesia, Requiring general anesthesia during the surgical procedure, Being hospitalized for more than 24 hours, Having a recurrent anal fistula, Having another anorectal disease besides the anal fistula, such as advanced Crohn's disease or colorectal cancer, Having complications within 24 hours of surgery and rescheduling surgery, Having visual, auditory, or cognitive problems, Having agreed to participate in the study but wishing to withdraw during follow-up.","90 Years",{"count":177,"type":21},76,[24],"It is emphasized that discharge education should shift from traditional healthcare provider-centered, one-way education to patient-centered education based on patient-care provider interaction to ensure patients' active participation in their own care, adherence to the recommended treatment plan, and maintenance of surgical success after outpatient anal fistula surgery. In this context, it is suggested that an effective education method such as teach-back can be used in clinical settings to teach patients complex health information and facilitate their understanding of discharge education. While studies exist in the literature evaluating the impact of health literacy after general surgery, no studies have been found specifically evaluating health literacy and discharge education for anal fistula surgery. Furthermore, it is emphasized that further research is needed to improve the quality of postoperative care after anal fistula surgery and to better understand the factors contributing to unplanned hospital returns. Based on this need, this study is a randomized controlled trial with a pretest and posttest approach aimed at determining the effect of teach-back-based discharge education on hospital readmission and patient satisfaction in outpatient anal fistula surgery patients. The study sample was calculated as a total of 68 people, 34 in each group, based on a power analysis performed with the GPower 3.1. 9.7 program, using a type 1 error of 0.05, a type 2 error of 0.20, and an effect size of 0.70 to determine the difference in measurements between the groups. Considering the possible attrition in the study, the sample size was increased by 10%, and a total of 76 people, 38 in each group, were planned to be included in the study. Following Ethics Committee approval and institutional permissions, the study data will be collected using the Individual Identification Form, Health Literacy Scale, Anal Fistula Surgery Discharge Education Knowledge Test, Discharge Satisfaction Scale, and Post-Discharge Follow-up Form, from patients scheduled for and undergoing outpatient anal fistula surgery at Muğla Training and Research Hospital between November 15, 2025, and January 30, 2027. The research will be conducted in three phases: the development of the education brochure and knowledge test, and the preoperative and postoperative phases. The \"Anal Fistula Surgery Discharge Education Knowledge Test\" was developed to assess patients' knowledge of anal fistula and its care. The \"Anal Fistula Surgery Discharge Education Patient Booklet\" was developed by the researchers using literature review and consultation with a General Surgery Specialist specializing in anal fistulas to provide specific training on anal fistula surgery and postoperative care. These were then sent to specialists for expert opinion. All patients presenting to the General Surgery Outpatient Clinic for anal fistula surgery who meet the inclusion criteria will be interviewed face-to-face before surgery to be informed about the study. Patients who agree to participate will be asked to sign a consent form. Because outpatient surgeries involve admission and discharge within 24 hours, and patients arrive at the Proctology Unit on the day of surgery, all patients will be summoned to the General Surgery Outpatient Clinic the day before surgery and will complete the \"Individual Identification Form,\" \"Health Literacy Scale,\" and \"Anal Fistula Surgery Discharge Education Knowledge Test.\" Patients will be assigned to the intervention (discharge education via teach-back) and control groups using a block randomization table based on their order of admission to the Proctology Unit for the surgical procedure. Patients in the intervention group will receive discharge education via teach-back using the \"Anal Fistula Surgery Discharge Education Patient Booklet.\" Education will continue until the patient accurately recounts the information to the principal investigator and is confident that the patient has understood the instruction correctly. The control group will receive standard patient education in the clinic and will not receive any intervention. Postoperatively, all patients in both groups will complete the \"Anal Fistula Surgery Discharge Education Knowledge Test\" post-test and the Discharge Education Satisfaction Scale before being discharged from the unit. Patients in both groups will be contacted weekly for 30 days to monitor their progress. Because the study will provide training, blinding of the assessments will not be possible.",[28,181,182],"Patient Discharge Education","Outpatient Anal Surgery",[184],"Anal fistula, Day surgery, Discharge teaching, Patient satisfaction, Readmission","2025-12-23",{"date":187,"type":42},"2026-01-07",{"date":189,"type":21},"2025-12-31",{"date":191,"type":21},"2027-05-15",{"name":193,"class":75},"Muğla Sıtkı Koçman University",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":50},"100377156","phase-1-e-cel-uvec-as-an-adjunct-cell-therapy-for-treatment-of-anal-fistulas-100377156","NCT04190862","E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas","An Open-Label, Single-Center, Investigator Initiated Phase 1B Trial of E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas","Inclusion Criteria:\n\n* Subject ages 18 or older\n* Subject willing and able to provide informed consent\n* Subject is medically eligible and have agreed to undergo a fistulotomy\n* Subject with simple perianal fistula with 2 or fewer fistula tracts\n* Maximum tract length of 3 inches\n* Subject without history of Crohn's disease\u002F Ulcerative Colitis\n* For female subjects of childbearing potential:\n* A negative serum or urine pregnancy test at screening is required prior to enrollment\n* Subject must be willing to use a highly effective method of contraception from the start of the screening period throughout the study period\n* For males who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception:\n* Subject must be willing to use a recommended method of contraception and refrain from sperm donation from the start of the conditioning therapy for at least 1 year after completion and discussion with a treating physician\n\nExclusion Criteria:\n\n* Concomitant rectovaginal fistulas\n* Subjects with an abscess\n* Presence of active infections findings (e.g.; redness, swelling, tenderness or fever)\n* Presence of rectal and\u002For anal stenosis\n* The presence of setons unless removed prior to the treatment\n* Subjects with ongoing steroid treatment or treated with steroids in the last 4 weeks\n* Renal impairment defined by creatinine clearance below 90 mL\u002Fmin calculated using Cockcroft-Gault formula or by serum creatinine ≥ 1.5 x upper limit of normality (ULN)\n* Hepatic impairment defined by both of the following laboratory ranges:\n* Total bilirubin ≥ 1.5 x ULN unless benign congenital hyperbilirubinemia\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥ 2.5 x ULN\n* Known history of abuse of alcohol or other addictive substances in the 6 months prior to enrollment\n* Active malignant tumor within 5 years\n* Current recent history of abnormal, severe, progressive, uncontrolled hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral diseases\n* Congenital or acquired immunodeficiencies including human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)\n* Major surgery or severe trauma within the previous 6 months\n* Subjects who are candidates for solid organ transplantation or who may have a high likelihood of needing a solid organ transplant (ex. progressive heart failure)\n* Females who are who are pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment\n* Subjects who have known hypersensitivity or documented allergy to DMSO\n* Subjects who do not wish to or cannot comply with study procedures\n* Subjects currently receiving, or having received any investigational drug within 3 months prior to E-CEL UVEC cell therapy",{"count":202,"type":21},39,[204],"PHASE1","The purpose of this study is to determine if endothelial cells derived from human umbilical vein are safe for use in conjunction with fistulotomy for the treatment of simple anal fistulas. Endothelial cells are a special kind of cell in the body that line the inside surface of blood vessels. The goal of the study is to evaluate the preliminary safety of human umbilical vein cells in anal fistula healing.",[28],"2025-11-14",{"date":209,"type":42},"2025-11-18",{"date":211,"type":42},"2020-01-22",{"date":213,"type":21},"2032-06-30",{"name":215,"class":75},"Weill Medical College of Cornell University",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":225,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":237},"100488571","a-double-blind-randomized-controlled-study-evaluating-the-safety-and-efficacy-of-rd2-ver02-for-the-management-of-anal-fistulas-100488571","NCT05641844","A Double Blind, Randomized Controlled Study, Evaluating the Safety and Efficacy of RD2 Ver.02 For the Management of Anal Fistulas","A Prospective, Multi-Center, Double Blind, Randomized Controlled Study, Evaluating the Safety and Efficacy of RD2 Ver.02, For the Management of Anal Fistulas","Inclusion Criteria:\n\n* Subject is ≥18 years of age\n* Subject has a transsphincteric or long intersphincteric anal fistula (\\>1.5 cm), with a seton in place for a minimum of 1 month, deemed eligible for primary or repeat fistula repair by anorectal advancement flap or LIFT: Anterior, posterior or lateral fistula, first or recurrent, at any position circumferentially, with one external opening and one internal opening.\n* Subjects is unable or unwilling to receive invasive surgical procedures, anorectal advancement flap or LIFT procedure, and is opting for minimally invasive technique of anal fistula management (i.e., fistula tract debridement and suturing of internal opening).\n* 2.1.4 Prior to enrollment, during the preceding 3 months from Treatment Visit, subject must undergo a pelvic MRI to evaluate eligibility criteria unable to be assessed clinically.\n* Female subjects who are capable of conceiving and all males capable of insemination must use an acceptable form of contraception in order to participate in the study and for 6 months following study procedure (acceptable forms of contraception include condoms for males and contraceptive pills or IUDs for women)\n\nExclusion Criteria:\n\n* Subject who has a life expectancy of less than 24 months.\n* Subjects who are cognitively impaired and have a healthcare proxy or those who are cognitively impaired and clearly do not understand the contents of the informed consent form.\n* Cannot withdraw blood in the required amount (up to 15 mL).\n* Women who are pregnant or currently breast feeding.\n* Subject is currently receiving (i.e., within the past 30 days) or scheduled to receive systemic steroids (more than 10mg per day).\n* Multiple fistula tracts, as confirmed on pelvic MRI\n* Short fistula tract that in the surgeon's opinion are amenable to fistulotomy\n* Active infection including perianal infection, and\u002For any active systemic or local infection.\n* Presence of a perirectal abscess on pelvic MRI\n* Presence of dominant luminal active Crohn's disease, validated by recent colonoscopy from preceding 12 months, requiring immediate therapy\n* Rectal and\u002For anal stenosis and \u002F or active proctitis, if this means a limitation for any surgical procedure.\n* Known allergies or hypersensitivity to any of the following: antibiotics including but not limited to penicillin, streptomycin, gentamicin, aminoglycosides; Human Serum Albumin (HSA); Dulbecco Modified Eagle's Medium (DMEM); materials of bovine origin; local anaesthetics or gadolinium (MRI contrast); Known hypersensitivity to reagents and components of RD2 Ver.02 including calcium gluconate, Kaolin or citrate and ethylene oxide.\n* Contraindication to MRI scan, (e.g., due to the presence of pacemakers, hip replacements, or severe claustrophobia).\n* Known coagulation problems, abnormal thrombocytes level or if heparin is given intravenously. Subjects who are taking Coumadin, Aspirin, Plavix (Clopidogrel), Eliquis or Pradaxa will not be excluded.\n* Patients with increased risk for the surgical procedure or major alteration of any of the following laboratory tests:\n\n  1. Serum Creatinine levels \\>1.5 times the upper limit of normality (ULN)\n  2. Total bilirubin \\>1.5 times the ULN (unless predominantly non conjugated due to documented history of Gilbert's syndrome)\n  3. AST\u002F ALT \\>3.0 times the ULN\n  4. Hemoglobin \\\u003C10.0 g\u002FdL\n  5. Platelets \\\u003C150.0 x109\u002FL\n  6. Albuminemia \\\u003C3.0 g\u002FdL.\n* Patients who do not wish to or cannot comply with study procedures.\n* Patients currently receiving or having received within 12 months prior to enrolment into this clinical study, any investigational drug.\n* Subjects who need surgery in the perianal region for reasons other than fistulas at the time of inclusion in the study, or for whom such surgery is foreseen in this region in the 24 weeks after treatment administration.\n* Contraindication to the anesthetic procedure.\n* Subject with a diagnosis of Ulcerative Colitis\n* Subject with malignancy, undergoing active treatment\n* Rectovaginal fistula\n* History of pelvic radiation",{"count":224,"type":21},110,[24],"The goal of this clinical trial is to assesses the safety of autologous RD2 Ver.02 as compared to a control for managing transsphincteric and intersphinsteric anal fistulas.\n\nThe main questions it aims to answer are:\n\nAssess the safety and efficacy of RD2 Ver.02 in anal fistula application, compared to control.\n\nComplication rate by 6 months of anal fistula treatment with RD2 Ver.02 compared to control.\n\nRecurrence of anal fistula at 12 months post-treatment Incidence of perirectal infection by 6 months in anal fistulas treated with RD2 Ver.02 compared to control.\n\nPatients will be randomized in to 2 arms. For all patients, blood will be drawn to ensure the blinding of the patients, the fistula will be evaluated and debrided, and then the internal fistula opening will be suture-closed, and a water leak test will be performed to ensure sealing. Following the water leak test, In the treatment arm, the patient's own coagulating blood will be applied into the entire fistula tract, allowing it to clot and serve as a provisional matrix inside the fistula tract. In the control arm, the blood sample will be discarded and saline will be applied to the fistula tract.",[28],"2025-11-12",{"date":230,"type":42},"2025-11-13",{"date":232,"type":42},"2024-01-20",{"date":234,"type":21},"2028-06-30",{"name":236,"class":165},"RedDress Ltd.",10,{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":245,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":251,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":50},"100599198","study-on-repeat-liposomal-bupivacaine-for-post-surgery-pain-in-anal-fistula-patients-100599198","NCT07081373","Study on Repeat Liposomal Bupivacaine for Post-Surgery Pain in Anal Fistula Patients.","Efficacy of Repeat Dosing of Liposomal Bupivacaine on Postoperative Pain in Patients With Anal Fistula: A Multicenter, Randomized, Open-Label, Controlled Study","Inclusion Criteria:\n\n* Diagnosed with anal fistula and scheduled to undergo anal fistula surgery;\n* Aged between 18 and 60 years;\n* ASA (American Society of Anesthesiologists) physical status class I-II;\n* Patient provides written informed consent after understanding the study protocol.\n\nExclusion Criteria:\n\n* Anal fistula caused by specific etiologies (e.g., tuberculosis);\n* Concurrent acute perianal skin infection;\n* Poorly controlled diabetes (HbA1c \\>9%);\n* Chronic use of corticosteroids;\n* History of radiotherapy or chemotherapy within the past 2 weeks;\n* Pregnancy or lactation;\n* Hypersensitivity to local anesthetics or any component of the investigational drug;\n* History of substance abuse, illicit drug use, or alcohol abuse;\n* Use or planned use of non-opioid\u002Fopioid analgesics within 12 hours before\u002Fduring surgery;\n* Concurrent treatment with anticonvulsants, MAO inhibitors, antidepressants, neuromuscular blockers, or anticholinergics within 2 weeks prior to surgery;\n* Severe hepatic\u002Frenal impairment, cardiopulmonary dysfunction, coagulation disorders, or comorbidities contraindicating surgery;\n* History of severe psychiatric disorders or cognitive impairment;\n* Sensory disorders (e.g., hyperalgesia) or preexisting pain interfering with postoperative pain assessment;\n* Contraindications to amide-type local anesthetics, opioids, or propofol;\n* Participation in investigational drug trials within 90 days prior to enrollment;\n* Other clinical\u002Flaboratory conditions deemed by investigators to preclude trial participation.","60 Years",{"count":247,"type":21},408,[24],"Anal Fistula refers to an abnormal infectious fistula tract between the anorectum and the perianal skin. The prevalence of anal fistula is approximately 8.6 cases per 100,000 individuals. It can occur at any age but is relatively more common in individuals aged 20-40 years, with a higher incidence in males than females.\n\nPostoperative wound management is a critical component of the overall treatment for anal fistula patients. Regular postoperative wound care, such as dressing changes, can reduce recurrence rates, alleviate pain, and shorten hospitalization time. However, postoperative pain remains a major challenge in wound management following anal fistula surgery. This is largely attributed to inadequate current postoperative analgesic protocols.\n\nWith ongoing advancements in local anesthetics, liposomal bupivacaine has been applied for postoperative analgesia. It offers higher bioavailability and a prolonged half-life, providing up to 72 hours of sustained analgesic effect. Given the limitations of existing analgesic strategies for post-anal fistula surgery, developing more effective pain management approaches to reduce postoperative pain holds significant clinical importance.\n\nTherefore, the investigators propose that a repeat-dosing strategy based on liposomal bupivacaine may provide superior postoperative pain control for anal fistula patients. To investigate this, the investigators designed a prospective, multicenter, randomized, open-label, controlled clinical trial. This study aims to evaluate the efficacy and safety of repeat-dose liposomal bupivacaine for postoperative analgesia following anal fistula surgery, thereby generating high-level evidence to support its clinical application in this context.",[28],[31,252,253,254],"Bupivacaine liposome","Postoperative pain","Repeat dosing","2025-07-15",{"date":257,"type":42},"2025-07-23",{"date":259,"type":21},"2025-07-16",{"date":261,"type":21},"2027-06-30",{"name":263,"class":75},"Sixth Affiliated Hospital, Sun Yat-sen University",{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":272,"targetDuration":274,"studyType":61,"phases":4,"briefSummary":275,"conditions":276,"keywords":278,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":4},"100594445","machine-learning-based-risk-stratification-for-fistula-formation-after-perianal-abscess-drainage-100594445","NCT07019532","Machine Learning-Based Risk Stratification for Fistula Formation After Perianal Abscess Drainage","A Prospective Cohort Study for Machine Learning-Based Prediction of Anal Fistula Formation After Perianal Abscess Drainage Based on Drainage Setting, Provider Experience, and MRI Interpretation (PRISM)","PRISM","Inclusion Criteria:\n\n* Age ≥ 18\n* First-time perianal abscess\n* Surgical drainage performed\n\nExclusion Criteria:\n\n* Existing anal fistula history\n* Crohn's disease\n* Immunosuppressive treatment\n* Incomplete 6-month follow-up",{"count":273,"type":21},450,"6 Months","This prospective cohort study investigates the influence of provider experience and drainage location on fistula formation within 6 months following perianal abscess drainage. Additionally, the study explores the role of artificial intelligence (AI)-based interpretation of magnetic resonance (MR) images in early identification of fistula development.",[277,28],"Perianal Abscess",[279,280,281,282,283,284],"Artificial Intelligence","MR Imaging","Colorectal Surgery","Surgical Outcomes","Drainage","Fistula Prediction","2025-06-05",{"date":287,"type":42},"2025-06-13",{"date":289,"type":21},"2025-07-01",{"date":291,"type":21},"2026-06-01",{"name":293,"class":49},"Gumushane State Hospital",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":302,"targetDuration":304,"studyType":61,"phases":4,"briefSummary":305,"conditions":306,"keywords":649,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":692,"lastUpdatePostDateStruct":693,"startDateStruct":695,"completionDateStruct":697,"leadSponsor":699,"locationsCount":701},"100193378","rare-disease-patient-registry--natural-history-study---coordination-of-rare-diseases-at-sanford-100193378","NCT01793168","Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford","Coordination of Rare Diseases at Sanford","CoRDS","Inclusion Criteria:\n\n* Diagnosis of a rare disease, a disease of unknown prevalence, undiagnosed or an unaffected carrier of a rare\u002Funcommon disease\n\nExclusion Criteria:\n\n* Diagnosis of a disease which is not rare",{"count":303,"type":21},20000,"100 Years","CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, individuals and researchers to help in the advancement of research in over 7,000 rare diseases. The registry is free for patients to enroll and researchers to access. Visit sanfordresearch.org\u002FCoRDS to enroll.",[307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404,405,406,407,408,409,410,411,412,413,414,415,416,417,418,419,420,421,422,423,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496,497,498,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,524,525,526,527,528,529,530,531,532,533,534,535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,576,577,578,579,580,581,582,583,584,585,586,587,588,28,589,590,591,592,593,594,595,596,597,598,599,600,601,602,603,604,605,606,607,608,609,610,611,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,629,630,631,632,633,634,635,636,637,638,639,640,641,642,643,644,645,646,647,648],"Rare Disorders","Undiagnosed Disorders","Disorders of Unknown Prevalence","Cornelia De Lange Syndrome","Prenatal Benign Hypophosphatasia","Perinatal Lethal Hypophosphatasia","Odontohypophosphatasia","Adult Hypophosphatasia","Childhood-onset Hypophosphatasia","Infantile Hypophosphatasia","Hypophosphatasia","Kabuki Syndrome","Bohring-Opitz Syndrome","Narcolepsy Without Cataplexy","Narcolepsy-cataplexy","Hypersomnolence Disorder","Idiopathic Hypersomnia Without Long Sleep Time","Idiopathic Hypersomnia With Long Sleep Time","Idiopathic Hypersomnia","Kleine-Levin Syndrome","Kawasaki Disease","Leiomyosarcoma","Leiomyosarcoma of the Corpus Uteri","Leiomyosarcoma of the Cervix Uteri","Leiomyosarcoma of Small Intestine","Acquired Myasthenia Gravis","Addison Disease","Hyperacusis (Hyperacousis)","Juvenile Myasthenia Gravis","Transient Neonatal Myasthenia Gravis","Williams Syndrome","Lyme Disease","Myasthenia Gravis","Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome)","Isolated Klippel-Feil Syndrome","Frasier Syndrome","Denys-Drash Syndrome","Beckwith-Wiedemann Syndrome","Emanuel Syndrome","Isolated Aniridia","Axenfeld-Rieger Syndrome","Aniridia-intellectual Disability Syndrome","Aniridia - Renal Agenesis - Psychomotor Retardation","Aniridia - Ptosis - Intellectual Disability - Familial Obesity","Aniridia - Cerebellar Ataxia - Intellectual Disability","Aniridia - Absent Patella","Aniridia","Peters Anomaly - Cataract","Peters Anomaly","Potocki-Shaffer Syndrome","Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11","Silver-Russell Syndrome Due to Imprinting Defect of 11p15","Silver-Russell Syndrome Due to 11p15 Microduplication","Syndromic Aniridia","WAGR Syndrome","Wolf-Hirschhorn Syndrome","4p16.3 Microduplication Syndrome","4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome","Autosomal Recessive Stickler Syndrome","Stickler Syndrome Type 2","Stickler Syndrome Type 1","Stickler Syndrome","Mucolipidosis Type 4","X-linked Spinocerebellar Ataxia Type 4","X-linked Spinocerebellar Ataxia Type 3","X-linked Intellectual Disability - Ataxia - Apraxia","X-linked Progressive Cerebellar Ataxia","X-linked Non Progressive Cerebellar Ataxia","X-linked Cerebellar Ataxia","Vitamin B12 Deficiency Ataxia","Toxic Exposure Ataxia","Unclassified Autosomal Dominant Spinocerebellar Ataxia","Thyroid Antibody Ataxia","Sporadic Adult-onset Ataxia of Unknown Etiology","Spinocerebellar Ataxia With Oculomotor Anomaly","Spinocerebellar Ataxia With Epilepsy","Spinocerebellar Ataxia With Axonal Neuropathy Type 2","Spinocerebellar Ataxia Type 8","Spinocerebellar Ataxia Type 7","Spinocerebellar Ataxia Type 6","Spinocerebellar Ataxia Type 5","Spinocerebellar Ataxia Type 4","Spinocerebellar Ataxia Type 37","Spinocerebellar Ataxia Type 36","Spinocerebellar Ataxia Type 35","Spinocerebellar Ataxia Type 34","Spinocerebellar Ataxia Type 32","Spinocerebellar Ataxia Type 31","Spinocerebellar Ataxia Type 30","Spinocerebellar Ataxia Type 3","Spinocerebellar Ataxia Type 29","Spinocerebellar Ataxia Type 28","Spinocerebellar Ataxia Type 27","Spinocerebellar Ataxia Type 26","Spinocerebellar Ataxia Type 25","Spinocerebellar Ataxia Type 23","Spinocerebellar Ataxia Type 22","Spinocerebellar Ataxia Type 21","Spinocerebellar Ataxia Type 20","Spinocerebellar Ataxia Type 2","Spinocerebellar Ataxia Type 19\u002F22","Spinocerebellar Ataxia Type 18","Spinocerebellar Ataxia Type 17","Spinocerebellar Ataxia Type 16","Spinocerebellar Ataxia Type 15\u002F16","Spinocerebellar Ataxia Type 14","Spinocerebellar Ataxia Type 13","Spinocerebellar Ataxia Type 12","Spinocerebellar Ataxia Type 11","Spinocerebellar Ataxia Type 10","Spinocerebellar Ataxia Type 1 With Axonal Neuropathy","Spinocerebellar Ataxia Type 1","Spinocerebellar Ataxia - Unknown","Spinocerebellar Ataxia - Dysmorphism","Non Progressive Epilepsy and\u002For Ataxia With Myoclonus as a Major Feature","Spasticity-ataxia-gait Anomalies Syndrome","Spastic Ataxia With Congenital Miosis","Spastic Ataxia - Corneal Dystrophy","Spastic Ataxia","Rare Hereditary Ataxia","Rare Ataxia","Recessive Mitochondrial Ataxia Syndrome","Progressive Epilepsy and\u002For Ataxia With Myoclonus as a Major Feature","Posterior Column Ataxia - Retinitis Pigmentosa","Post-Stroke Ataxia","Post-Head Injury Ataxia","Post Vaccination Ataxia","Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract","Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus","Non-hereditary Degenerative Ataxia","Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity","Olivopontocerebellar Atrophy - Deafness","NARP Syndrome","Myoclonus - Cerebellar Ataxia - Deafness","Multiple System Atrophy, Parkinsonian Type","Multiple System Atrophy, Cerebellar Type","Multiple System Atrophy","Maternally-inherited Leigh Syndrome","Machado-Joseph Disease Type 3","Machado-Joseph Disease Type 2","Machado-Joseph Disease Type 1","Leigh Syndrome","Late-onset Ataxia With Dementia","Infection or Post Infection Ataxia","GAD Ataxia","Hereditary Episodic Ataxia","Gliadin\u002FGluten Ataxia","Friedreich Ataxia","Fragile X-associated Tremor\u002FAtaxia Syndrome","Familial Paroxysmal Ataxia","Exposure to Medications Ataxia","Episodic Ataxia With Slurred Speech","Episodic Ataxia Unknown Type","Episodic Ataxia Type 7","Episodic Ataxia Type 6","Episodic Ataxia Type 5","Episodic Ataxia Type 4","Episodic Ataxia Type 3","Episodic Ataxia Type 1","Epilepsy and\u002For Ataxia With Myoclonus as Major Feature","Early-onset Spastic Ataxia-neuropathy Syndrome","Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity","Early-onset Cerebellar Ataxia With Retained Tendon Reflexes","Early-onset Ataxia With Dementia","Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia","Dilated Cardiomyopathy With Ataxia","Cataract - Ataxia - Deafness","Cerebellar Ataxia, Cayman Type","Cerebellar Ataxia With Peripheral Neuropathy","Cerebellar Ataxia - Hypogonadism","Cerebellar Ataxia - Ectodermal Dysplasia","Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss","Brain Tumor Ataxia","Brachydactyly - Nystagmus - Cerebellar Ataxia","Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia","Autosomal Recessive Syndromic Cerebellar Ataxia","Autosomal Recessive Spastic Ataxia With Leukoencephalopathy","Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay","Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria","Autosomal Recessive Spastic Ataxia","Autosomal Recessive Metabolic Cerebellar Ataxia","Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine","Autosomal Recessive Ataxia, Beauce Type","Autosomal Recessive Ataxia Due to Ubiquinone Deficiency","Autosomal Recessive Ataxia Due to PEX10 Deficiency","Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia","Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency","Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency","Autosomal Recessive Congenital Cerebellar Ataxia","Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome","Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency","Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency","Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency","Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome","Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity","Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency","Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect","Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion","Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation","Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness","Autosomal Recessive Cerebellar Ataxia","Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly","Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation","Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy","Autosomal Dominant Spastic Ataxia Type 1","Autosomal Dominant Spastic Ataxia","Autosomal Dominant Optic Atrophy","Ataxia-telangiectasia Variant","Ataxia-telangiectasia","Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy","Autosomal Dominant Cerebellar Ataxia Type 4","Autosomal Dominant Cerebellar Ataxia Type 3","Autosomal Dominant Cerebellar Ataxia Type 2","Autosomal Dominant Cerebellar Ataxia Type 1","Autosomal Dominant Cerebellar Ataxia","Ataxia-telangiectasia-like Disorder","Ataxia With Vitamin E Deficiency","Ataxia With Dementia","Ataxia - Oculomotor Apraxia Type 1","Ataxia - Other","Ataxia - Genetic Diagnosis - Unknown","Acquired Ataxia","Adult-onset Autosomal Recessive Cerebellar Ataxia","Alcohol Related Ataxia","Multiple Endocrine Neoplasia","Multiple Endocrine Neoplasia Type II","Multiple Endocrine Neoplasia Type 1","Multiple Endocrine Neoplasia Type 2","Multiple Endocrine Neoplasia, Type IV","Multiple Endocrine Neoplasia, Type 3","Multiple Endocrine Neoplasia (MEN) Syndrome","Multiple Endocrine Neoplasia Type 2B","Multiple Endocrine Neoplasia Type 2A","Atypical Hemolytic Uremic Syndrome","Atypical HUS","Wiedemann-Steiner Syndrome","Breast Implant-Associated Anaplastic Large Cell Lymphoma","Autoimmune\u002FInflammatory Syndrome Induced by Adjuvants (ASIA)","Hemophagocytic Lymphohistiocytosis","Behcet's Disease","Alagille Syndrome","Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD)","Lowe Syndrome","Pitt Hopkins Syndrome","1p36 Deletion Syndrome","Jansen Type Metaphyseal Chondrodysplasia","Cockayne Syndrome","Chronic Recurrent Multifocal Osteomyelitis","CRMO","Malan Syndrome","Hereditary Sensory and Autonomic Neuropathy Type Ie","VCP Disease","Hypnic Jerking","Sleep Myoclonus","Mollaret Meningitis","Recurrent Viral Meningitis","CRB1","Leber Congenital Amaurosis","Retinitis Pigmentosa","Rare Retinal Disorder","KCNMA1-Channelopathy","Primary Biliary Cirrhosis","ZMYND11","Transient Global Amnesia","Glycogen Storage Disease","Alstrom Syndrome","White Sutton Syndrome","DNM1","EIEE31","Myhre Syndrome","Recurrent Respiratory Papillomatosis","Laryngeal Papillomatosis","Tracheal Papillomatosis","Refsum Disease","Nicolaides Baraitser Syndrome","Leukodystrophy","Tango2","Cauda Equina Syndrome","Rare Gastrointestinal Disorders","Achalasia-Addisonian Syndrome","Achalasia Cardia","Achalasia Icrocephaly Syndrome","Congenital Sucrase-Isomaltase Deficiency","Eosinophilic Gastroenteritis","Idiopathic Gastroparesis","Hirschsprung Disease","Rare Inflammatory Bowel Disease","Intestinal Pseudo-Obstruction","Scleroderma","Short Bowel Syndrome","Sacral Agenesis","Sacral Agenesis Syndrome","Caudal Regression","Scheuermann Disease","SMC1A Truncated Mutations (Causing Loss of Gene Function)","Cystinosis","Juvenile Nephropathic Cystinosis","Nephropathic Cystinosis","Kennedy Disease","Spinal Bulbar Muscular Atrophy","Warburg Micro Syndrome","Mucolipidoses","Mitochondrial Diseases","Mitochondrial Aminoacyl-tRNA Synthetases","Mt-aaRS Disorders","Hypertrophic Olivary Degeneration","Non-Ketotic Hyperglycinemia","Fish Odor Syndrome","Halitosis","Isolated Congenital Asplenia","Lambert Eaton (LEMS)","Biliary Atresia","STAG1 Gene Mutation","Coffin Lowry Syndrome","Borjeson-Forssman-Lehman Syndrome","Blau Syndrome","Arginase 1 Deficiency","HSPB8 Myopathy","Beta-Mannosidosis","TBX4 Syndrome","DHDDS Gene Mutations","MAND-MBD5-Associated Neurodevelopmental Disorder","Constitutional Mismatch Repair Deficiency (CMMRD)","SPATA5 Disorder","SPATA5L1 Related Disorder","Acrodysostosis","Multi-systematic Smooth Muscle Dysfunction Syndrome","CRELD1 (Cysteine Rich With EGF Like Domains 1)","GNB1 Syndrome","Pyruvate Dehydrogenase Complex Deficiency Disease","Beta Mannosidosis","Kbg Syndrome","Labrune Syndrome","Metachromatic Leukodystrophy (MLD)","Moyamoya Disease","OPHN1 Syndrome","Oculopharyngeal Muscular Dystrophy (OPMD)","TUBB3 Mutation","WOREE (WWOX-related Epileptic Encephalopathy","SCAR12","Skraban-Deardorff Syndrome","Hereditary Myopathy With Early Respiratory Failure",[650,651,652,653,654,361,655,656,368,657,327,658,659,660,531,540,661,662,318,663,664,326,665,328,666,317,667,668,543,669,670,546,547,671,549,550,672,673,553,674,675,676,602,677,678,679,680,681,682,683,607,684,685,686,612,613,687,688,689,690,691],"Rare Diseases","Neglected Diseases","Orphan Diseases","Rare Disease Research","Registries","Ataxia","Cornelia de Lange Syndrome","Ataxia Telangiectasia","Batten Disease","Mucolipidosis IV","Klippel-Feil Syndrome","Undiagnosed","Uncommon Disease","Hypersomnia","Hyperacusis","Marinesco-Sjogren Syndrome","4p-\u002FWolf-Hirschhorn Syndrome","Narcolepsy","Wiedermann-Steiner Syndrome","Autoimmune\u002Finflammatory Syndrome Induced by Adjuvants (ASIA)","Hemophagocytic Lymphohistiocytosis (HLH)","Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia (IBMPFD)","1p36 deletion syndrome","Jansen metaphyseal chondrodysplasia","Chronic recurrent multifocal osteomyelitis (CRMO)","Malan syndrome","Hereditary Sensory and Autonomic Neuropathy","Juvenile nephropathic cystinosis","Nephropathic infantile cystinosis","Ocular cystinosis","Kennedy disease","Spinal Bulbar Muscular Atrophy (SBMA)","SMC1A Truncated Mutations (causing loss of gene function)","Leigh syndrome","Mucolipidosis","Mitochondrial aminoacyl-tRNA synthetases (Mt-aaRS Disorders)","Shine Syndrome","Intestinal Bromhidrosis Syndrome","Fish odor syndrome","Autosomal recessive extra oral halitosis","CACNA1H mutation","Dimethylglycine dehydrogenase deficiency","2025-05-22",{"date":694,"type":42},"2025-05-29",{"date":696,"type":42},"2010-07",{"date":698,"type":21},"2100-12",{"name":700,"class":75},"Sanford Health",2,{"id":703,"slug":704,"hasResults":11,"nctId":705,"briefTitle":706,"officialTitle":707,"acronym":4,"eligibilityCriteria":708,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":709,"enrollmentInfo":710,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":712,"conditions":713,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":714,"lastUpdatePostDateStruct":715,"startDateStruct":717,"completionDateStruct":719,"leadSponsor":721,"locationsCount":4},"100590039","cross-cultural-adaptation-of-the-chinese-version-of-qolaf-q-quality-of-life-in-patients-with-anal-fistula-questionnaire-a-multi-center-study-100590039","NCT06962228","Cross-cultural Adaptation of the Chinese Version of QoLAF-Q (Quality of Life in Patients With Anal Fistula Questionnaire) ：A Multi-center Study","A Multicenter Observational Cross-sectional Clinical Trial of Cross-cultural Adaptation of the Chinese Version of QoLAF-Q (Quality of Life in Patients With Anal Fistula Questionnaire)","Inclusion Criteria:\n\n1. meeting the diagnostic criteria for anal fistula in the \"Diagnostic Criteria for Anal Fistula (2004 Edition)\", and being diagnosed through clinical examinations, digital rectal examinations, anorectal ultrasound, MRI, and other examinations;\n2. being 18 years old or above;\n3. having clear consciousness and being able to understand and cooperate to complete the questionnaire survey;\n4. voluntarily signing the informed consent form.\n\nExclusion Criteria:\n\n1. having other serious anorectal diseases, such as anal fissure, rectal prolapse, colorectal cancer, etc.;\n2. having severe dysfunction of important organs such as the heart, liver, and kidneys;\n3. suffering from mental diseases or having cognitive impairments;\n4. having undergone anorectal surgery or other major surgeries that may affect the quality of life recently (within 3 months).","80 Years",{"count":711,"type":21},150,"The investigators verify the reliability and practicality of the Chinese adaptation results of QoLAF-Q, which helps Chinese doctors better master the methods and techniques of quality of life assessment.",[28],"2025-04-29",{"date":716,"type":42},"2025-05-08",{"date":718,"type":21},"2025-05-01",{"date":720,"type":21},"2025-08-31",{"name":722,"class":75},"Changhai Hospital",{"id":724,"slug":725,"hasResults":11,"nctId":726,"briefTitle":727,"officialTitle":728,"acronym":4,"eligibilityCriteria":729,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":730,"enrollmentInfo":731,"targetDuration":4,"studyType":22,"phases":732,"briefSummary":733,"conditions":734,"keywords":738,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":744,"lastUpdatePostDateStruct":745,"startDateStruct":747,"completionDateStruct":749,"leadSponsor":751,"locationsCount":50},"100577842","effect-of-enhanced-recovery-after-surgery-for-benign-anorectal-conditions-100577842","NCT06803550","Effect of Enhanced Recovery After Surgery for Benign Anorectal Conditions","Effect of Enhanced Recovery After Surgery in Reducing the Incidence of Postoperative Urinary Retention After Surgery for Benign Anorectal Conditions: a Randomized Controlled Trial","Inclusion Criteria:\n\n* both sexes\n* aged between 18 and 65 years old\n* presented with benign anorectal conditions including chronic anal fissure, hemorrhoids, and fistula-in-ano will be eligible for the study\n\nExclusion Criteria:\n\n* younger than 18\n* older than 65 years old\n* pregnant female\n* history of relevant urological diagnosis (benign prostatic hyperplasia\u002Fprostate cancer\u002Furethral stricture\u002Fbladder neck stenosis\u002Fdetrusor underactivity\u002Fdetrusor overactivity)\n* history of relevant urological procedure (radical prostatectomy\u002F transurethral prostatectomy\u002Fbladder neck or urethral surgery\u002Fpelvic radiotherapy)\n* use of permanent urinary catheter\n* intraoperative urological procedures\n* with any form of urinary diversion\n* severe cognitive impairment\n* who undergo other anorectal procedures","65 Years",{"count":85,"type":21},[24],"This study aims to assess the role of Enhanced recovery after surgery(ERAS) protocol in reducing postoperative urine retention (POUR) after surgery for benign anorectal conditions.",[28,735,736,737],"Anal Fissure Chronic","Haemorrhoid","Enhanced Recovery After Surgery (ERAS) Protocol",[739,740,741,31,742,743],"ERAS","Postoperative urinary retention","Benign anorectal conditions","Anal fissure","Haemorrhoids","2025-01-30",{"date":746,"type":42},"2025-02-03",{"date":748,"type":42},"2024-12-17",{"date":750,"type":21},"2025-06-30",{"name":752,"class":75},"Mansoura University",{"id":754,"slug":755,"hasResults":11,"nctId":756,"briefTitle":757,"officialTitle":758,"acronym":759,"eligibilityCriteria":760,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":761,"targetDuration":4,"studyType":22,"phases":763,"briefSummary":765,"conditions":766,"keywords":767,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":770,"lastUpdatePostDateStruct":771,"startDateStruct":773,"completionDateStruct":775,"leadSponsor":777,"locationsCount":50},"100539431","phase-1-tissue-therapy-of-transsphincteric-anal-fistula-100539431","NCT06303752","Tissue Therapy of Transsphincteric Anal Fistula","Repairing Peri-Anal Fistulas With Regenerative Cell Therapeutics","REP-PAF","Inclusion criterion:\n\nAdult patients (\\>= 18years) with complex anal fistula (high transsphincteric or suprasphincteric), with involvement of more 30% of the anal sphincter referred to the surgical department at Odense University Hospital for treatment, and who are:\n\n* able to communicate with Danish language\n* able to provide informed consent\n* having address in the region of southern Denmark during the study\n\nExclusion criteria:\n\n1. Signs of suppuration\u002Fcavitation around the fistula\n2. Simple or low anal fistula, which can be treated by simple surgical incision\n3. Ano-vaginal and recto-vaginal fistula\n4. The presence of more than one fistula tract, more than two external orifices or more than one internal orifice\n5. Inflammatory Bowel Disease\n6. Immunosuppression (due to clinical condition or medical therapy)\n7. Malignancy within 5 years\n8. Previous radiotherapy of the abdomen and pelvis\n9. BMI under 18.5\n10. Allergy against the antibiotics: Penicillin and streptomycin.\n11. Coagulopathy\n12. Pregnancy and lactation (positive HCG (human chorionic gonadotropin) test)\n13. Verified syphilis, HIV, or hepatitis on screening test",{"count":762,"type":21},75,[204,764],"PHASE2","This clinical study aims to evaluate the outcome of the treatment of complex perianal fistulas (PAF) by the combination of minimal surgical debridement with regenerative cellular therapeutics.",[28],[173,768,769],"stem cells","ADRC","2024-11-02",{"date":772,"type":42},"2024-11-05",{"date":774,"type":42},"2024-10-09",{"date":776,"type":21},"2028-10-08",{"name":778,"class":75},"University of Southern Denmark",{"id":780,"slug":781,"hasResults":11,"nctId":782,"briefTitle":783,"officialTitle":783,"acronym":4,"eligibilityCriteria":784,"healthyVolunteers":785,"sex":16,"minAge":17,"maxAge":709,"enrollmentInfo":786,"targetDuration":274,"studyType":61,"phases":4,"briefSummary":788,"conditions":789,"keywords":790,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":794,"lastUpdatePostDateStruct":795,"startDateStruct":797,"completionDateStruct":799,"leadSponsor":801,"locationsCount":50},"100558254","patients-quality-of-life-and-functional-changes-after-fistula-surgery-100558254","NCT06548724","Patient's Quality of Life and Functional Changes After Fistula Surgery","Inclusion Criteria:\n\n* both genders\n* Age :between 18-65 years\n* cryptoglandular anal fistula\n* need intervention\n\nExclusion Criteria:\n\n\\- Patients with associated anorectal pathology (anal fissure, hemorrhoids, rectal prolapse, neoplasm, solitary rectal ulcer, inflammatory bowel diseases.)",true,{"count":787,"type":21},70,"This is a prospective observational study that will monitor the effects of surgery for anal fistula on the patient quality of life using many valid questionnaires",[28],[96,791,792,793],"incontinence","preoperative","postoperative","2024-08-09",{"date":796,"type":42},"2024-08-12",{"date":798,"type":42},"2021-08-01",{"date":800,"type":21},"2024-12",{"name":802,"class":75},"Mansoura University Hospital",{"id":804,"slug":805,"hasResults":11,"nctId":806,"briefTitle":807,"officialTitle":807,"acronym":4,"eligibilityCriteria":808,"healthyVolunteers":11,"sex":16,"minAge":809,"maxAge":245,"enrollmentInfo":810,"targetDuration":4,"studyType":22,"phases":812,"briefSummary":813,"conditions":814,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":815,"lastUpdatePostDateStruct":816,"startDateStruct":818,"completionDateStruct":820,"leadSponsor":822,"locationsCount":4},"100523190","role-of-autologous-platelet-rich-plasmaprp-injection-and-platelet-rich-fibrin-glueprfg-interposition-for-treatment-of-anal-fistula-100523190","NCT06092398","Role of Autologous Platelet Rich Plasma(PRP) Injection and Platelet Rich Fibrin Glue(PRFG) Interposition for Treatment of Anal Fistula","Inclusion Criteria:\n\n* 60 patients with perianal fistula were in the age group between 20 to 60 years old\n\nExclusion Criteria:\n\n* Thrombocytopenia\n* Patient with rectovaginal fistula\n* fistula with chronic cavities\n* Acute sepsis and patient were not willing undergo this type of treatment","20 Years",{"count":811,"type":21},60,[24],"To evaluate the autologous platelet rich plasma and platelet rich fibrin glue effect on the treatment of anal fistula\n\nTo asses role of platelet rich plasma and platelet rich fibrin glue in decreasing recurrence of perianal fistula",[28],"2023-10-15",{"date":817,"type":42},"2023-10-23",{"date":819,"type":21},"2024-09",{"date":821,"type":21},"2028-04",{"name":129,"class":75}]